← Back to Search

Behavioral Intervention

Perturbation Training for Alzheimer's Disease (STAD Trial)

Verified Trial
N/A
Recruiting
Led By Feng Yang, PhD
Research Sponsored by Georgia State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants can read and understand English
Participants must be able to walk independently at least 25 feet
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trialwill look at how people w/ Alzheimer's learn to reduce falls through special training.

Who is the study for?
This trial is for English-speaking individuals aged 65 or older with probable Alzheimer's Disease who can walk and stand independently. They must have certain scores on cognitive tests indicating moderate impairment but cannot have had perturbation training before, osteoporosis, other major psychiatric or neurological conditions, injuries, or uncontrolled blood pressure issues.
What is being tested?
The study is testing the effectiveness of perturbation training in teaching people with Alzheimer's Disease how to resist falls better. Perturbation training involves controlled exposure to disturbances that challenge balance.
What are the potential side effects?
While specific side effects are not listed for this type of physical training, participants may experience fatigue, muscle soreness, or discomfort from the exercises involved in perturbation training.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk by myself for at least 25 feet.
Select...
I can stand on my own for at least 30 seconds.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Lab-induced faller rate
Secondary study objectives
Dynamic stability
Number of prospective fall incident
Other study objectives
Berg Balance Scale
Mobility
Muscle strength
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Training groupExperimental Treatment1 Intervention
This arm will receive a single-session perturbation training treatment on a treadmill under the protection of a safety harness.
Group II: Control groupPlacebo Group1 Intervention
This arm will not receive perturbation training but will go through harnessed walking on the same treadmill for the same time as the other group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perturbation training
2021
N/A
~140

Find a Location

Who is running the clinical trial?

Georgia State UniversityLead Sponsor
65 Previous Clinical Trials
30,676 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,172,088 Total Patients Enrolled
Alzheimer's AssociationOTHER
99 Previous Clinical Trials
43,414 Total Patients Enrolled
Feng Yang, PhDPrincipal InvestigatorGeorgia State University
3 Previous Clinical Trials
150 Total Patients Enrolled

Media Library

Perturbation training (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05205980 — N/A
Alzheimer's Disease Research Study Groups: Control group, Training group
Alzheimer's Disease Clinical Trial 2023: Perturbation training Highlights & Side Effects. Trial Name: NCT05205980 — N/A
Perturbation training (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05205980 — N/A
~7 spots leftby Jun 2025